



Immunotec Inc. – Election of new Director

Vaudreuil-Dorion, Quebec, March 30, 2009 – IMMUNOTEC INC.

(TSX Venture Exchange: IMM) (the "Company" or "Immunotec"), is engaged primarily in the development, manufacturing and marketing of health and wellness products which are classified as dietary supplements or natural health products. These products are distributed and sold in Canada, the United States and Korea through a network marketing system and exported in other countries under exclusive distributorship agreements.

NEW MEMBER OF THE BOARD OF DIRECTORS

Immunotec announces that, at its Annual Shareholders' Meeting held on March 25th, all of the nominees proposed by the Board of Directors were elected by the shareholders. The number of directors was increased from eight to nine, the new director being, Mr. Robert Dépatie.

Mr. Dépatie is the President and Chief Executive Officer of Vidéotron Ltd. a position he has held since June 2003. He joined Vidéotron Ltd. in December 2001 as Principal Vice President of Sales, Marketing and Customer Service. Prior to joining Vidéotron Ltd., Mr. Dépatie held many high level positions in the food distribution industry, such as President of Distributions alimentaires Le Marquis/Planters. From 1988 to 1996, he held various positions with H.J. Heinz Canada Ltd. Mr. Dépatie began his career in sales with Bessy's Foods and Nabisco Canada. He serves as a Director of Cable Television Laboratories, Inc. and of CF Cable TV Inc. and Vidéotron (regional) Ltd.

The Board of Directors of Immunotec now consists of the following members: Messrs. Dieter Beer, Robert Dépatie, Alex Konigsberg, Jean La Couture, James A. Northrop, Charles L. Orr, Richard M. Patte, Charles H. Roberts and Donald G. Watt.

GRANT OF STOCK OPTIONS

Immunotec announces that its Board of Directors granted, on March 25th, a total of 150,000 stock options to its independent directors. Each of the Immunotec directors, except for Messrs. James A. Northrop, Richard M. Patte and Charles H. Roberts, received 25,000 stock options. Each of these options have an exercise price of \$0.45, which was the closing price of the common shares on the TSX-V as of March 24, 2009, and each expires five years after the date of the grant and is subject to the terms and conditions of the Immunotec Stock Option Plan and the TSX Venture Exchange policies.

CHANGE TO THE AUDIT COMMITTEE

Immunotec announces that the composition of its Audit Committee has been modified by the replacement of Mr. Don Watt by Mr. Robert Dépatie.

The Company's Audit Committee consists of three members of the Board of Directors: Messrs. Robert Dépatie, Alex Konigsberg and Jean La Couture, Chair of the Committee.

IMMUNOTEC

Immunotec is located in a 37,000 square foot facility located in Vaudreuil-Dorion, Quebec, Canada and also has a manufacturing facility located in Blainville, Quebec, Canada and a distribution centre located in Swanton, Vermont, USA. Immunotec is engaged primarily in the development and marketing of natural health products, dietary supplements, food, vitamins and personal care products, and natural health products, some of which are manufactured on its behalf by third parties. Immunotec's products are distributed and sold in Canada, the United States and Korea through a network marketing system and exported in other countries under exclusive distributorship agreements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact: Richard Patte, CA, Chief Financial Officer, tel.: (450) 510-4445